Access cutting-edge sarcoma treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access sarcoma specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related sarcoma treatment provided free
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthrac
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this sarcoma clinical trial in Los Angeles, CA
If you're searching for sarcoma treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.